Tim Illidge, BSc, PhD, MRCP, FRCR, FRCPath
Professor of Targeted Therapy and Oncology
School of Cancer and Imaging Sciences
University of Manchester
Manchester Academic Health Science Centre
Manchester Cancer Research Centre
The Christie NHS Foundation Trust
Manchester, United Kingdom
School of Cancer and Imaging Sciences
University of Manchester
Manchester Academic Health Science Centre
Manchester Cancer Research Centre
The Christie NHS Foundation Trust
Manchester, United Kingdom
Last modified: November 26, 2018
Authored Items
Does radiotherapy remain an important component in the standard of care for patients with early stage Hodgkin lymphoma?
FAQ published on April 9, 2014
What are the most common adverse events associated with brentuximab vedotin?
FAQ published on January 15, 2014
What is the role of imaging biomarkers using FDG-PET in the treatment of early-stage Hodgkin lymphoma?
FAQ published on August 21, 2013